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On the 100th anniversary of Alzheimer’s lecture de-
scribing the clinicopathological entity which bears
his eponym, this article reviews the major areas of
progress in our understanding of the disease and
outlines the many gaps still remaining. The progress
toward effective mechanistic therapy is reviewed.
On November 3, 1906, Alois Alzheimer gave a lecture to
the Meeting of the Psychiatrists of South West Germany,
presenting the neuropathological and clinical descrip-
tion of the features of one of his cases, Auguste D.,
who had died of a dementing illness at the age of 55,
having been brought to his attention by her worried
family at the age of 51 (Alzheimer, 1907). In his short de-
scription he discussed the clinical features of her case
(which, while clearly including a progressive dementia,
is actually rather unusual for our present expectation
of the disease), and he also described the pathological
features he observed in her brain, which included the
presence of plaques (miliary foci) and tangles (fibrils).
Alzheimer was not the first to describe the clinical fea-
tures of the disease (which have been documented in
the elderly since the ancient Greeks), nor was he the first
to describe the plaques (Redlich, 1898). He does, how-
ever, seem to have been the first to describe the tangles
(Perusini, 1991); these pathological advances were
enabled by the development of silver stains (Bielschow-
sky, 1902). The disease was given his eponym by his
senior colleague, Kraepelin (1910), almost certainly, in
part, because of his statement that he was describing
a new disease entity:
‘‘We must not be satisfied to force it into the
existing group of well known disease patterns.’’
This description initiated the slow separation, using
clinicopathologic criteria, between Alzheimer’s disease
and other causes of presenile dementia, which included
Pick’s disease, Creuzfeldt-Jakob disease, and Gerst-
mann Straussler and Worster Drought syndromes.
The silver stained slides of Auguste D.’s brain have
recently been rediscovered, and their examination has
confirmed that we currently use the term Alzheimer’s
disease to describe the same diagnostic entity (Maurer
*Correspondence: hardyJ@mail.nih.govet al., 1997; Graeber et al., 1998). Unfortunately, no fam-
ily history information is given for Auguste D., and so we
do not know whether she had the autosomal dominant
form of the disease. It is likely that, as molecular biolog-
ical techniques are improved, this will be assessed
through PCR amplification of her DNA from the silver
stained sections of her brain. We already know that
Auguste D. was an apolipoprotein E3 homozygote
(Graeber et al., 1998).
After Kraepelin’s naming of the disease, the term was
usually used to describe cases with a presenile (classi-
cally, less than 65 years) onset age, although Kraepelin’s
paper discusses this issue, as do other authors’ over the
years (Kraepelin, 1910; Newton, 1948; see also Beach,
1987). Often, in these early case descriptions (which of
course predate molecular staining techniques), it is not
clear whether any particular case has what we would
now describe as Alzheimer’s disease or one of the other
dementias, most usually a variant of prion disease. Late
onset ‘‘senile dementia’’ was barely studied and was
generally ascribed to hardening of the arteries: a con-
cept, which though long out of favor, may indeed hold
an element of truth (Atwood et al., 2002).
The first autosomal dominant cases of Alzheimer’s
disease were described by Schottky (1932), Van Bogaert
and Maert (1940), and Essen-Moller (1946). Although the
family described by Schottky was lost to followup, the
families described by van Bogaert were used over 50
years later in chromosome 14 linkage studies (Van
Broeckhoven et al., 1992), and the family described by
Essen-Moller underwent one of the first documented
instances of genetic counseling when their disease
was found to be caused by a presenilin mutation
(Gustafson et al., 1998).
The modern era of Alzheimer’s research started with
the realization that the majority of cases with senile de-
mentia actually had Alzheimer’s pathology, changing
Alzheimer’s disease from a rare neurological curiosity
to a major research priority. In a series of influential
papers, Blessed, Tomlinson, and Roth made the obser-
vation that the majority of cases of what had been called
‘‘senile dementia’’ had the plaque and tangle pathology
of Alzheimer’s disease (Blessed et al., 1968; Tomlinson
et al., 1968, 1970). While the separation between
‘‘Alzheimer’s disease’’ (with an age of onset of <65
years) and Senile Dementia of the Alzheimer Type
(SDAT) (with an age of onset of >65 years) was main-
tained for several years, it became clear that under-
standing the biology of Alzheimer’s disease would
help in the development of an understanding of the
causes of dementia in the elderly, and the nosological
separation was dropped (Katzman, 1976). The formation
of Alzheimer’s Associations in the United States in 1979
and later in other countries and increased research
funding followed from this realization (Khachaturian,
2006).
Three basic science research tracks were pursued to
try to develop an understanding of the disease. The first,
inspired by the remarkable success of the neurochemi-
cal pathology work of Carlsson and Hornykiewicz on
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to develop an understanding of any possible selective
neurotransmitter loss in Alzheimer’s (Hornykiewicz,
2002). This approach has led to the currently available
therapies, largely based on cholinergic cell loss. The
second track approached the disease through the
understanding of its pathognomic lesions, the neuritic
plaque and the neurofibrillary tangle, and the third track
took a positional cloning strategy in Mendelian forms of
Alzheimer’s to find the causative variants behind the
disease etiology. Unexpectedly, the positional cloning
strategy and the pathology approach led to a convergent
outcome, which has led to an integrated approach
to trying to develop an understanding of the disease
pathogenesis.
The Neurochemical Approach
In 1976, a fairly selective deficit in cortical markers of
cholinergic neurons was discovered in a number of
patients (Davies and Maloney, 1976; Bowen et al.,
1976; Perry et al., 1977). At the time, the source of the
origin of cortical innervation was not known, but was
soon discovered to be in the basal forebrain (Wenk
et al., 1980) where there was shown to be profound neu-
ronal damage (Whitehouse et al., 1982). In parallel with
this literature showing loss of cortical innervation from
the nucleus basalis in Alzheimer’s disease was work
on experimental animals and human volunteers showing
the importance of cholinergic transmission in memory
formation (Davis et al., 1978; Bartus, 1979). This com-
bined literature led to the prevalent view that modulating
cholinergic transmission might offer a rational route
to the symptomatic treatment of Alzheimer’s disease.
The first, flawed study of a cholinesterase inhibitor
(Summers et al., 1986) was followed by other therapies
based on cholinesterase inhibition. Currently, nearly all
approved therapies are based on cholinesterase inhibi-
tion, but these are only marginally effective, without
affecting the course of the illness (Lleo et al., 2006).
There are probably several reasons why cholinesterase
inhibitors have only marginal efficacy, but among them
is almost certainly the fact that the selectivity of the
disease process for cholinergic innervation was greatly
overstated. From the earliest days of neurochemical in-
vestigation, it was clear that catecholamine innervation
to the cortex was also affected (Adolfsson et al., 1979),
and the most prominent pathology in Alzheimer’s is neu-
rofibrillary tangles in cortical pyramidal neurons, the ma-
jority of which probably use glutamate as a transmitter
(Hardy et al., 1987). Thus, the transmitter replacement
approach to Alzheimer’s therapy has likely reached the
limit of its potential.
Dissecting the Composition of the Lesions
The first stage in the examination of the structure of the
pathognomic Alzheimer’s lesions was by electron
microscope. Kidd (1963) identified the structure of the
tangles as consisting of paired helical filaments, and
Terry et al. (1964) detailed the complex structure of the
neuritic plaque and its content of amyloid fibers. Miya-
kawa and Uehara (1979) described the close physical
relationship between the amyloid angiopathy in the dis-
ease and the neuritic plaques, and implied that the am-
yloid in these lesions was likely to be chemically similar.Determining the chemical compositions of the fibrils in
both the plaques and the angiopathic vessels, and the
chemical compositions of the paired helical filaments
of the tangles, took careful biochemical analysis. Glen-
ner and Wong (1984a, 1984b) derived the partial se-
quence of Ab (which Glenner called b-amyloid) from
the angiopathic meningeal vessels of both Alzheimer’s
disease and Down’s syndrome. The abstract of his
paper on Down’s syndrome (Glenner and Wong,
1984b) is remarkable for its prescient suggestion that fa-
milial Alzheimer’s disease could be caused by a muta-
tion of the amyloid gene and its prediction that overex-
pression of the gene would also cause disease.
Masters et al. (1985) derived the same sequence (which
they called A4 because they thought the pathogenic
species was an oligomer, possibly tetrameric) from pla-
ques, and these findings led to the cloning of the APP
gene in 1987 and its localization, as predicted, to chro-
mosome 21 (Goldgaber et al., 1987; Kang et al., 1987).
Tau had previously been identified as a protein in-
volved in microtubule assembly (Weingarten et al.,
1975). Its identification as the central component of the
tangles was made through antigenic analysis (Brion
et al., 1985; Wood et al., 1986; Kosik et al., 1986; Nukina
and Ihara, 1986), through protein purification methods
(Grundke-Iqbal et al., 1986), and eventually, through di-
rect sequencing of the isolated pair helical filament
peptides (Goedert et al., 1988). Tau protein in the tangles
was shown to be phosphorylated (48), which was widely
believed to underlie its abnormal deposition.
Positionally Cloning the Genes Involved
in Alzheimer’s Pathogenesis
Although the first genetic linkage using DNA technolo-
gies was to Duchenne Muscular Dystrophy (Murray
et al., 1982), it was the localization of the Huntington’s
gene to chromosome 4 in 1983 which awakened the
neuroscience community to the power of the positional
cloning strategy in finding genes for disease (Gusella
et al., 1983). The application of molecular genetics to
the problem of Alzheimer’s disease got off to a false,
but prescient, start. Contemporaneously with the clon-
ing of the APP gene described above, the first genetic
linkage studies reported that the APP gene and the
Alzheimer’s locus were one and the same (St George-
Hyslop et al., 1987a; Tanzi et al., 1987a), and further
reports indicated that the locus was duplicated in
some cases of Alzheimer’s disease (Delabar et al.,
1987). All these reports were wrong in the families stud-
ied (Tanzi et al., 1987b): the families used for the linkage
study were later shown to be chromosome 14-linked (St
George-Hyslop et al., 1992), and the duplication report
seems simply to have been in error (St George-Hyslop
et al., 1987b). However, later events proved that the
ideas behind these findings had merit (see below).
Genetic analysis of families with Alzheimer’s disease
showed that some families did indeed show linkage to
chromosome 21 markers (Goate et al., 1989), but that
the disease was genetically heterogeneous (Schellen-
berg et al., 1988; St George-Hyslop et al., 1990). At this
time, Frangione and colleagues had shown that Ab
was deposited in the blood vessel walls in hereditary
cerebral hemorrhage with amyloidosis, Dutch type
(HCHWA-D) (van Duinen et al., 1987). Van Broeckhoven
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Broeckhoven et al., 1990; Levy et al., 1990) showed
that an APP mutation underpinned this disorder. With
this background, focused sequencing of the APP gene
in those Alzheimer’s families that showed evidence for
genetic linkage to chromosome 21 identified APP muta-
tions (Goate et al., 1991). The precise positions of these
mutations showed that their most likely effect was to
alter APP processing (Goate et al., 1991; Murrell et al.,
1991; Chartier-Harlin et al., 1991; Mullan et al., 1992;
Hardy, 1992) (see below). More recently, APP duplica-
tions in families with a variant of Alzheimer’s disease
have indeed been discovered (Rovelet-Lecrux et al.,
2006), and this, together with the absence of Alzheimer’s
disease in Down’s syndrome patients who were trisomic
distal of the APP locus (Prasher et al., 1998), clearly
shows that APP overexpression can be a cause of Alz-
heimer’s. Thus, the two errors of Alzheimer’s linkage to
the APP locus and APP duplication published in 1987
turned out to be presciently correct in families other
than the ones in which they were reported.
In general, families with APP mutations have a typical
Alzheimer’s disease phenotype (Mullan et al., 1993), al-
though some mutations, including theAPP duplications,
have a phenotype reminiscent of HCHWA-D (van Duinen
et al., 1987; Levy et al., 1990; Rovelet-Lecrux et al., 2006;
Hendriks et al., 1992). The age of onset of cases with
APP mutations is typically in the late 40s to mid 50s.
Both cases with APP mutations and cases with Down’s
syndrome can have Lewy bodies as well as tangles
(Lantos et al., 1994; Lippa et al., 1999).
The majority of families with autosomal dominant Alz-
heimer’s disease did not have APP mutations. In 1992,
Schellenberg and colleagues identified linkage to chro-
mosome 14 (Schellenberg et al., 1992), and in 1995, St.
George-Hyslop and colleagues identified presenilin 1
as the major locus underlying the early onset autosomal
dominant disease (Sherrington et al., 1995). Genetic
analysis had shown that a group of German families
from Russia (the Volga Germans) did not show linkage
to chromosome 14 markers (Levy-Lahad et al., 1995a),
but rather showed linkage to genetic markers on chro-
mosome 1 (75). A homolog of presenilin 1, presenilin 2,
mapped to this region and was shown to underlie the
remaining few cases of the autosomal dominant disease
(Levy-Lahad et al., 1995a, 1995b; Rogaev et al., 1995). In
general, cases with presenilin 1 mutations also have typ-
ical Alzheimer’s disease with an age of onset in the late
30s to mid 40s (Martin et al., 1991) though some cases
present with spastic paraparesis and have unusual
‘‘cotton wool’’ plaques (Crook et al., 1998). Cases with
presenilin 2 mutations also have features similar to
typical Alzheimer’s disease, but the onset ages are
more variable, even within a family (Bird et al., 1989).
Cases with presenilin mutations also frequently have
Lewy body pathology (Lippa et al., 1998).
ApoE as a Risk Factor for Late Onset
Alzheimer’s Disease
In 1991, Roses and his colleagues reported genetic link-
age to late onset Alzheimer’s disease to chromosome 19
markers (Pericak-Vance et al., 1991) and then identified
apolipoprotein E, encoded on this chromosome, as an
Ab binding protein (Strittmatter et al., 1993). Geneticanalysis showed that a common variant of this gene,
apoE4, was a risk factor for disease (Corder et al.,
1993), and that another common variant, apoE2, was
negatively associated with disease (Chartier-Harlin
et al., 1994). These remarkable findings are among the
most replicated findings in biology (Roses, 2006). They
appear to account for about a third of the population-
attributable risk for developing Alzheimer’s disease
(Farrer et al., 1995). However, the mechanism behind
this association remains unclear, with most authorities
suspecting a role in amyloid deposition (Holtzman,
2004). Despite extensive work, no other genetic risk fac-
tors for late onset disease have been validated (Bertram
and Tanzi, 2004).
MAPT Mutations and a-Synuclein Mutations
All cases of autosomal dominant, early onset Alz-
heimer’s disease reported to date have mutations in
either the APP or the presenilin genes. In 1994, Wilhelm-
sen and colleagues described genetic linkage to chro-
mosome 17 makers in a family with a progressive de-
mentia syndrome (Wilhelmsen et al., 1994). The clinical
phenotype of this syndrome was very variable and
included some cases that were clinically very similar to
Alzheimer’s disease (Foster et al., 1997). A key observa-
tion was that the majority of these cases had tau pathol-
ogy, including, in some cases, neurofibrillary tangles
(Spillantini et al., 1998). Levy-Lahad and colleagues
and Hutton and colleagues (Poorkaj et al., 1998; Hutton
et al., 1998) showed that all those cases with tau pathol-
ogy had MAPT mutations. These data showed that
tangles could be directly initiated by MAPT mutations
and were extremely useful for animal modeling (see
below).
Lewy bodies have long been recognized as a frequent
part of the pathology of Alzheimer’s disease (Hansen
et al., 1993), but are pathognomic of Parkinson’s dis-
ease. In 1996, Nussbaum and colleagues showed that
mutations in the a-synuclein gene were one cause of
the disorder (Polymeropoulos et al., 1997), and subse-
quently, Spillantini and colleagues showed that a-synu-
clein was the major protein component of Lewy bodies
(Spillantini et al., 1997). These data parallel those for
MAPT reviewed above and show that Lewy bodies
could be directly initiated by a-synuclein mutations.
Making Transgenic Models of Alzheimer’s Pathology
Finding the genes involved in Alzheimer’s pathogenesis
has provided the information necessary to make partial
models of the disease process. APP transgenic mice
develop plaques, but they don’t develop significant tau
pathology (Games et al., 1995), nor do they develop
extensive cell loss (Takeuchi et al., 2000). Crossing these
mice with presenilin mutant mice potentiates this exist-
ing pathology, but does not lead to cell loss or tau
pathology (Holcomb et al., 1998; Borchelt et al., 1997).
Such mice with plaques have memory decrements,
and brain slices from them show LTP abnormalities
which are Ab-dependent (Hsiao et al., 1996; Janus
et al., 2000; Morgan et al., 2000; Lesne et al., 2006),
although the relationship of these findings to the mem-
ory problems in Alzheimer’s disease, in which there is,
of course, extensive cell loss, is not clear.
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6Figure 1. Alzheimer’s versus an Alzheimer’s
Model
Image comparing tissue from an Alzheimer’s-
affected brain with tissue from a transgenic
mouse with APP and MAPT transgenes, cour-
tesy of Dr. Dennis Dickson (Lewis et al., 2001).
Production of mice with the whole pathology
of the disease has been a major step forward
for researchers, though the fact that such
mice have two overexpressing mutant genes
raises worries about data interpretation.Mutant MAPT transgenic mice develop tangle pathol-
ogy (Lewis et al., 2000), and these mice have severe cell
loss in those brain regions in which tangles develop.
Crossing these mice with APP transgenic mice potenti-
ates the tangle pathology and the cell loss, but does not
alter the plaque pathology (Lewis et al., 2001) (Figure 1),
making the interpretation that APP is upstream of tangle
pathology tenable (Hardy et al., 1998). While no a-synu-
clein transgenic mice develop Lewy bodies, the modest
pathology which has been observed to develop (Masliah
et al., 2000) is potentiated by crossing a-synuclein trans-
genic mice with APP mice (Masliah et al., 2001) suggest-
ing that the relationships between Ab and tau and Ab
and a-synuclein have parallels.
The Effects of Alzheimer-Causing Mutations
on APP Processing
Assessment of APP metabolism showed that it under-
went rapid turnover in cells (Weidemann et al., 1989)
and that Ab was a normal product of metabolism in vitro
and in vivo (Haass et al., 1992; Shoji et al., 1992). Analy-
sis of the metabolism of APP with the pathogenic APP
mutations showed that all of the pathogenic mutations
altered APP metabolism such that more Ab42 was
produced (Citron et al., 1992; Cai et al., 1993; Suzuki
et al., 1994). These data, together with the demonstra-
tion that Ab42 was the earliest species deposited in
Alzheimer’s disease (Iwatsubo et al., 1994) and the sug-
gestion that Ab was neurotoxic (Yankner et al., 1990),
formed the intellectual basis of the amyloid hypothesis
for the disorder (Selkoe, 1991; Hardy and Allsop, 1991;
Hardy and Higgins, 1992) and highlighted the impor-
tance of developing a molecular understanding of the
three cleavages around the Ab sequence: b-secretase,
responsible for the N-terminal cut of Ab from APP (at
APP 671); a-secretase, responsible for the alternative
cleavage of the shorter fragment p3 at around residue
17 of Ab (APP687); and g-secretase, responsible for re-
leasing both Ab and p3 from the relevant C-terminal
stubs of APP and cleaving intramembranously around
APP residues 711–713 (Haass and Selkoe, 1993).
What Are the Toxic Species of Ab and Tau?
A continued area of active research has been aimed at
understanding the potential mechanism of Ab toxicity.
While original formulations of the amyloid hypothesis
envisaged the deposited peptide as neurotoxic, it has
become increasingly clear that smaller species assem-
blies have both behavioral and electrophysiological
effects (Lambert et al., 1998; Walsh et al., 2002; Lesneet al., 2006). A similar discussion has related to the
understanding of the mechanism of cell death induced
by tau: while clearly tangles are a substantial space-fill-
ing lesion (Sumpter et al., 1986), recent data suggests
that the cell loss in MAPT transgenic mice has a more
complicated pathogenesis than this simple space-filling
effect (Santacruz et al., 2005).
APP Processing and Deposition as a Therapeutic
Target in Alzheimer’s Disease
b-Secretase
The identification of the Swedish mutation at the b-sec-
retase site (Mullan et al., 1992) illustrated the potential
value of modulating this cleavage for therapy. In an ele-
gant series of APP mutagenesis experiments, Citron and
colleagues showed that only the Swedish variant had
a greater flux though the b-secretase pathway, explain-
ing why only that single pathogenic mutation has been
found at that site and providing an assay to help identify
the enzyme responsible for it (Citron et al., 1995). Clon-
ing of the b-secretase (BACE) gene revealed it to be
a membrane-bound aspartyl protease (Vassar et al.,
1999). Genetic deletion of BACE1 in mice completely
abolishes Ab production and deposition and rescues
cognitive impairments in APP transgenic animals, sug-
gesting that BACE1 is a high-priority therapeutic target
for Alzheimer’s disease. However, there are several ca-
veats associated with BACE1 inhibition. While BACE1
knockout mice do not produce Ab and show no major
pathological abnormalities, they do display subtle defi-
cits in explorative activities as well as spatial learning
and memory, implying potential side effects in com-
pletely abolishing BACE1 activity (Ohno et al., 2004;
Laird et al., 2005). Additionally, validating it as a pharma-
cological target for Alzheimer’s treatment (Citron, 2004),
the large size of the active site of BACE1 (Hong et al.,
2000 has made designing selective inhibitors that can
pass through the blood-brain barrier a considerable
challenge (Citron, 2004). Since complete inhibition of
b- or g-secretase activity presents considerable side ef-
fects, a cocktail of BACE1 and g-secretase inhibitors
that partially suppress these two proteolytic activities
may serve as a better therapeutic strategy to block Ab
production.
a-Secretase
a-Secretase cleaves at position 16 of the Ab sequence
(APP687) (Esch et al., 1990). The cleavage does not ap-
pear to be sequence-specific, but rather appears to rely
on the maintenance of an a-helical domain at this point
(Sisodia, 1992). It is inhibited by some of the mutations
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disease, apparently because they disrupt this a-helical
sequence (De Jonghe et al., 1998). Much less work has
been carried out on the a-secretase cleavage because,
as a treatment strategy, one would want to potentiate
cleavage (Hooper and Turner, 2002), and this is per-
ceived to be more difficult than inhibiting cleavage by
b-secretase or g-secretase. However, it seems likely
that a-secretase cleavage is mediated by a mix of
the metalloproteases ADAM9, ADAM10, and ADAM17
(Asai et al., 2003).
g-Secretase
Analysis of tissues from presenilin mutation carriers and
transfected cells showed that the presenilin mutations,
like the APP mutations, increased the proportion of
Ab42 derived from APP processing (Scheuner et al.,
1996). Presenilins were shown to be involved in the
Notch pathway (Levitan and Greenwald, 1995), and
mice in which the presenilin gene was knocked out suf-
fered embryonic lethality (Wong et al., 1997). Cultured
primary neurons from presenilin knockout mice were un-
able to cleave the C-terminal fragment of APP, showing
that presenilins were intimately involved in this cleavage
(De Strooper et al., 1998), as well as the analogous
cleavage of Notch (De Strooper et al., 1999; Struhl and
Greenwald, 1999). Focused mutagenesis of two trans-
membrane aspartates in presenilin strongly suggested
that these were the residues responsible for the g-secre-
tase intramembranous cleavage (Wolfe et al., 1999), and
subsequent reconstitution experiments have conclu-
sively shown that presenilin and other components
(APH, PEN2, and Nicastrin) make up the core of the
g-secretase complex responsible for the cleavage of
APP, Notch, and other transmembrane proteins (Edba-
uer et al., 2003), with possibly other accessory proteins
contributing to the full complex (Chen et al., 2006).
While it is presumed that a lot off effort has been in-
vested by the pharmaceutical industry in developing
g-secretase inhibitors, surprisingly little has been pub-
lished. As discussed above, presenilin knockouts are
embryonically lethal (Wong et al., 1997). However, con-
ditional neuronal knockouts, and mice showing reduced
expression of presenilin, are viable, although they have
behavioral defects (Yu et al., 2001, Dewachter et al.,
2002) and harbor a potential for initiating tumorigenesis
(Xia et al., 2001). These data were interpreted as sug-
gesting that modest inhibition of g-secretase may be
a viable drug target despite its multifunctional role.
The most extensive work relevant to g-secretase
modulation has been published on the nonsteroidal
anti-inflammatory drugs (NSAIDS). Some of these com-
pounds, through a none-cyclo-oxygenase dependent
process, modify g-secretase activity (Weggen et al.,
2001). NSAIDS had been proposed as treatments for
Alzheimer’s disease based on the occurrence of many
markers of inflammation in the pathology of the disease
(McGeer and Rogers, 1992). However, these data sug-
gest that some such compounds may also be allosteric
modulators of the g-secretase cleavage.
Ab Immunization
In 1999, Schenk and colleagues (Schenk et al., 1999) re-
ported that Ab immunization of APP transgenic mice
massively reduced their amyloid pathology. The motiva-
tion behind these experiments was not clear, but itseems likely that the intention was to try and induce
tangle pathology and cell loss through activation of the
immune response (Webster et al., 1997). The observa-
tion that Ab immunization reduced amyloid pathology
was multiply confirmed and extended to passive Ab
immunization and the observation that the mice’s mem-
ory function improved (Morgan et al., 2000; Janus et al.,
2000). Neuropathological examination of individuals
with Alzheimer’s disease who died after receiving the
immunization revealed that it did indeed reduce amy-
loid, but not tau, pathology (Nicoll et al., 2003). Unfortu-
nately, however, the trial had to be stopped, because in
a proportion of the Alzheimer’s cases (though not in the
healthy volunteers) the immunization led to a meningo-
encephalitis (Winblad and Blum, 2003). It remains un-
clear whether this complication is related to the whole
approach of Ab immunization or to some idiosyncrasy
of the trial (Schenk, 2004; Atwood et al., 2003). No final
analyses of the clinical effects of the trial have been
reported (Winblad and Blum, 2003).
Other Treatment Approaches
The production and wide availability of transgenic mice
exhibiting many of the pathological features of the dis-
ease has enabled (relatively) quick and inexpensive
ways of testing therapies, largely against amyloid
deposition, but also, more recently, against tau pathol-
ogy (Noble et al., 2005). Most, but not all, of these
approaches have been framed around the amyloid hy-
pothesis of the disorder: besides NSAIDs, they include
metal chelators, antioxidants, cholesterol lowering
drugs, and tau phosphorylation inhibitors (Duff and Su-
leman, 2004). A surprising number of these approaches
have been successful in mice, and currently, many of
these approaches are in various stages of clinical trials.
Defining the Alzheimer’s Prodrome
A corollary of the attempts to develop mechanistic ther-
apy for Alzheimer’s disease, as opposed to the limited
palliative therapy now available, is the development of
better means of making the diagnosis of the Alzheimer’s
process at an early point. In this regard, the recognition
of mild cognitive impairment (MCI) as an important as-
pect of this prodrome has had considerable impact
(Petersen et al., 1999). MRI analysis of presenilin and
APP mutation carriers has clearly shown that the degen-
erative process begins several years before clinical
manifestations of the disease become evident (Scahill
et al., 2002); using an amyloid binding PET ligand, Klunk
and colleagues (Klunk et al., 2004) have developed
a methodology which may be useful both for identifying
people in the Alzheimer’s prodrome and monitoring the
efficacy of clinical trials.
Concluding Remarks
As reviewed above, there have been essentially three
periods of Alzheimer’s research (see also Table 1). The
first was the definition of the disease by clinicians and
pathologists. The second was the neurochemical
work, which led to the identification of the cholinergic le-
sion in the disease, and upon which current therapies
are based, and the third is the molecular biological and
molecular genetic approach to the dissection of the
pathogenesis. This last era of Alzheimer’s research
has paralleled work on other neurologic and psychiatric
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8Table 1. A Summary of the History of Research into Alzheimer’s
Disease and Related Disorders
Year
Related
Developments Alzheimer’s Disease
1902 Improved silver
stains
1906 Alzheimer’s case history of
Auguste D.
1910 Alzheimer’s Disease named
1922 Lewy body
described
1932 First hereditary case described
1962 L-dopa therapy in
Parkinson’s
1963/4 Ultrastructure of plaque and
tangle by electron microscopy
1968 Recognition of prevalence of
disease in the elderly
1976 Cholinergic deficit described
1983 Huntington’s genetic
linkage
Sequence of Ab from Alzheimer’s
amyloid angiopathy
1984 Sequence of Ab from Down’s
syndrome from amyloid
angiopathy
1985 Cloning of the prion
gene
Sequence of Ab from plaques
1986 Tau as major component of
tangles
1987 Cloning of APP and localization to
chromosome 21
1989 Mutations in prion
gene in CJD/GSS
1990 Mutations in APP
cause HCHWA-D;
prion mutations
cause
neurodegeneration
in mice
Alzheimer’s disease genetically
heterogeneous
1991 APP mutations in Alzheimer’s; a
descriptive system of
cataloguing the neuropathology
determined
1993 ApoE4 associated with
Alzheimer’s; cholinergic
therapy approved for AD
1994 APP mutations increase Ab42
1995 APP transgenic mice made with
plaque pathology; presenilins
cloned as loci for early onset
Alzheimer’s
1996 Presenilin mutations shown to
alter APP processing
1997 Synuclein mutations
identified in PD;
Synuclein
identified as major
component of
Lewy bodies
1998 Tau mutations
identified in
FTDP-17
Presenilins identified as
g-secretase
1999 BACE cloned; Ab immunization
in mice reduces amyloid
pathology
2000 Mice with tangles
made using FTDP-17
mutations
2001 Mice with plaques and tangles
made
2003 Ab vaccine trials halted because
of side effectsdiseases and undoubtedly holds great promise both for
dissecting disease pathogenesis and for developing
mechanism-based therapies. However, it has to be ac-
knowledged that no therapies for any neurologic or psy-
chiatric disease have, as yet, been developed by this ap-
proach.
By far, the prevailing hypothesis for disease patho-
genesis based on these molecular data is the amyloid
hypothesis, and as we approach the centenary of Alz-
heimer’s lecture, we are in a research limbo: many trials
of agents based on the amyloid hypothesis are either in
progress or being planned, but no completed, large-
scale, double blind trials have yet been reported. These,
of course, are the true test of the hypothesis, and will
be the outcome by which it will be judged. If we can
only treat the model disease in mice, it will not have
been useful.
There remain several large gaps in our knowledge: is
Ab toxicity observed in cell systems relevant to the
loss of neurons and to the disruption of memory and
cognitive function in the disease? If so, what is the
mechanism of Ab and tau toxicity? What is the relation-
ship, if any, between APP and tau or a-synuclein? What
is the function of APP, and what, if any, is the function of
Ab? In addition, we have little understanding as to the
reasons for the distinctive neuroanatomy of the disease
(Braak and Braak, 1991), and the spatial relationships
between the pathognomic lesions remain almost un-
studied (Duyckaerts, 2004). We also have very little un-
derstanding of the role of apolipoprotein E in disease
pathogenesis and, despite an enormous effort, we
have not found other convincing genetic or environmen-
tal risk factors. The last 100 years, and especially the last
40 years, since the disease was rediscovered by
Blessed, Tomlinson, and Roth has brought an enormous
amount of scientific progress in terms of understanding
the etiology of the disease. It has also brought a lot of
progress in social attitudes to the disease in the reduc-
tion of its associated stigma. Medical application of this
progress has, however, come slower and much remains
to be done in the second century of Alzheimer’s re-
search. If Auguste D. were alive today, her sad progno-
sis would be much the same as in 1906.
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